id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2015-E-3157-0006,FDA,FDA-2015-E-3157,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2017-09-21T04:00:00Z,2017,9,2017-09-21T04:00:00Z,,2017-09-21T13:00:35Z,,0,0,0900006482b696be
FDA-2015-E-3157-0005,FDA,FDA-2015-E-3157,"Determination of Regulatory Review Period for Purposes of Patent
Extension; TRULICITY",Notice,Determinations,2016-12-19T05:00:00Z,2016,12,2016-12-19T05:00:00Z,2017-06-20T03:59:59Z,2016-12-19T15:35:53Z,2016-30399,0,0,0900006482423949
FDA-2015-E-3157-0004,FDA,FDA-2015-E-3157,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-12-13T05:00:00Z,2016,12,2016-12-13T05:00:00Z,,2016-12-13T16:40:14Z,,0,0,0900006482401417
FDA-2015-E-3157-0003,FDA,FDA-2015-E-3157,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2015-10-15T04:00:00Z,2015,10,2015-10-15T04:00:00Z,,2015-10-15T20:09:09Z,,0,0,0900006481ccf54c
FDA-2015-E-3157-0001,FDA,FDA-2015-E-3157,Patent Extension Application from Eli Lilly and Company,Other,Application,2015-08-27T04:00:00Z,2015,8,2015-08-27T04:00:00Z,,2015-08-27T16:08:30Z,,0,0,0900006481c3e54c
FDA-2015-E-3157-0002,FDA,FDA-2015-E-3157,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2015-08-27T04:00:00Z,2015,8,2015-08-27T04:00:00Z,,2015-08-27T16:08:43Z,,0,0,0900006481c3df3a